Li_2009_J.Clin.Pharm.Ther_34_447

Reference

Title : Inter-individual variability of plasma PAF-acetylhydrolase activity in ARDS patients and PAFAH genotype - Li_2009_J.Clin.Pharm.Ther_34_447
Author(s) : Li S , Stuart L , Zhang Y , Meduri GU , Umberger R , Yates CR
Ref : J Clin Pharm Ther , 34 :447 , 2009
Abstract :

BACKGROUND: Platelet activating factor (PAF), a pro-inflammatory phospholipid, stimulates cytokine secretion from polymorphonuclear leukocytes expressing the transmembrane G-protein coupled PAF receptor. Elevated PAF levels are associated with acute respiratory distress syndrome (ARDS) and sepsis severity. The pro-inflammatory effects of PAF are terminated by PAF acetylhydrolase (PAF-AH). OBJECTIVE: We sought to determine whether allelic variants in the human PAFAH gene (Arg92His, Ile198Thr, and Ala379Val) contribute to variability in PAF-AH activity in patient plasma obtained within 72 h of ARDS diagnosis.
RESULTS: Plasma PAF-AH activity (mean +/- SD) was higher in patients homozygous for the Arg92 allele compared to His92 allele carriers (2.21 +/- 0.77 vs. 1.64 +/- 0.68 U/min; P < 0.01; n = 31 and 21 respectively). Baseline plasma PAF-AH activity was higher among day 7 survivors vs. day 7 non-survivors (2.05 +/- 0.75 vs. 1.27 +/- 0.63, P = 0.05). CONCLUSION: These data demonstrate an association between PAF-AH allelic variation, plasma activity, and outcome in ARDS.

PubMedSearch : Li_2009_J.Clin.Pharm.Ther_34_447
PubMedID: 19583678
Gene_locus related to this paper: human-PLA2G7

Citations formats

Li S, Stuart L, Zhang Y, Meduri GU, Umberger R, Yates CR (2009)
Inter-individual variability of plasma PAF-acetylhydrolase activity in ARDS patients and PAFAH genotype
J Clin Pharm Ther 34 :447

Li S, Stuart L, Zhang Y, Meduri GU, Umberger R, Yates CR (2009)
J Clin Pharm Ther 34 :447